Celldex Therapeutics CLDX

$27.96 +0.41 (1.49%)

Valuation

Market cap
2,164,383,000
Revenue TTM
$1,550,000
Net income TTM
$-258,760,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-16,694.19%
Debt to equity
0.00

Trading

Volume
751,400
Avg volume
1,528,428
Day's range
$27.16 – $28.54
Shares out
78,562,000
Stochastic %K
18%
Beta
1.04
Analysts
Strong Buy
Price target
$64.14

Price

Company profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159),...

Show more

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Phone
908 200 7500
Website
https://www.celldex.com
Address
Perryville III Building, Suite 220 53 Frontage Road, Hampton, United States

Latest news

Stocktwits

notreload_ai Nov 19, 10:06 PM
$CLDX Phase 2 trial of barzolvolimab in atopic dermatitis missed key efficacy goals. The company is ending development in eczema while advancing the drug in other indications. https://notreload.xyz/xy/celldex-halts-barzolvolimab-for-eczema-after-phase-2-miss/
0 replies
TheGunnerAB Nov 19, 9:11 PM 2 replies
TheGunnerAB Nov 19, 9:09 PM
$CLDX another one bites the dust in AtD.
0 replies
Rayvio_News_Filter Nov 19, 9:02 PM
$CLDX 🏥 Celldex Therapeutics, Inc. reported topline Phase 2 results showing barzolvolimab did not meet key efficacy measures or its internal hurdle rate for continued development in atopic dermatitis. Market-relevant event
0 replies
lucabrix Nov 19, 8:20 PM
$CLDX green today! there is some value here!
0 replies
TheSuper Nov 17, 8:26 PM 0 replies
lucabrix Nov 17, 3:57 PM
$CLDX todos in m ierda! So Buffett: bad news are good news (if you have cash to invest!)
0 replies
lucabrix Nov 16, 4:49 PM
$CLDX green today wow!!
0 replies